Scott Struthers
Oprichter bij CRINETICS PHARMACEUTICALS, INC.
Vermogen: 49 M $ op 30-04-2024
Actieve functies van Scott Struthers
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
CRINETICS PHARMACEUTICALS, INC. | Directeur/Bestuurslid | 01-11-2008 | - |
Algemeen Directeur | 01-12-2008 | - | |
Oprichter | 01-01-2008 | - | |
President | 01-12-2008 | - | |
The San Diego Entrepreneurs Exchange | Directeur/Bestuurslid | 01-01-2009 | - |
Oprichter | 01-01-2009 | - | |
Radionetics Oncology, Inc.
Radionetics Oncology, Inc. Pharmaceuticals: MajorHealth Technology Radionetics Oncology, Inc. is a clinical stage radiopharmaceutical company based in Menlo Park, CA. Radionetics Oncology, Inc. focuses on the discovery and development of novel radiotherapeutics for the treatment of various oncology indications. Radionetics Oncology spun out of Crinetics Pharmaceuticals and is supported by Frazier Life Sciences, 5AM Ventures, DCVC Bio, Crinetics Pharmaceuticals, and GordonMD Investments. The company is advancing a pipeline of small molecule radioligands that target G-protein coupled receptors to treat a wide range of cancers, including adrenocortical carcinoma, breast cancer, and lung cancer. The company's platform technology uses nonpeptide, small molecule targeting to deliver therapeutic radioisotopes selectively to tumors expressing peptide receptors. The company's pipeline consists of multiple lead drug candidates, and they are conducting additional drug discovery efforts in collaboration with Crinetics Pharmaceuticals. The market for radiopharmaceuticals is expected to rise to $12.6 billion by 2027. The company was founded by Scott R. Struthers, and Paul A. Grayson has been the CEO since 2024. | Voorzitter | 01-10-2021 | - |
Oprichter | 01-10-2021 | - |
Loopbaan van Scott Struthers
Eerdere bekende functies van Scott Struthers
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
NEUROCRINE BIOSCIENCES, INC. | Directeur/Bestuurslid | 01-01-1998 | 01-01-2008 |
Corporate Officer/Principal | 01-01-1998 | 01-01-2008 | |
ScienceMedia, Inc.
ScienceMedia, Inc. Electronics DistributorsDistribution Services ScienceMedia, Inc. provides marketing, communication, and e-learning solutions for life sciences and higher education markets. It offers solutions through the Web site and intranet, as well as through CD-ROMs. The company was founded by Arnold T. Hagler in 1995 and is headquartered in San Diego, CA. | Oprichter | 01-01-1995 | 01-01-1998 |
Opleiding van Scott Struthers
University of California San Diego | Doctorate Degree |
Statistieken
Internationaal
Verenigde Staten | 7 |
Operationeel
Founder | 4 |
Director/Board Member | 3 |
Chief Executive Officer | 1 |
Sectoraal
Health Technology | 4 |
Consumer Services | 2 |
Distribution Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
NEUROCRINE BIOSCIENCES, INC. | Health Technology |
CRINETICS PHARMACEUTICALS, INC. | Health Technology |
Bedrijven in privébezit | 3 |
---|---|
ScienceMedia, Inc.
ScienceMedia, Inc. Electronics DistributorsDistribution Services ScienceMedia, Inc. provides marketing, communication, and e-learning solutions for life sciences and higher education markets. It offers solutions through the Web site and intranet, as well as through CD-ROMs. The company was founded by Arnold T. Hagler in 1995 and is headquartered in San Diego, CA. | Distribution Services |
The San Diego Entrepreneurs Exchange | |
Radionetics Oncology, Inc.
Radionetics Oncology, Inc. Pharmaceuticals: MajorHealth Technology Radionetics Oncology, Inc. is a clinical stage radiopharmaceutical company based in Menlo Park, CA. Radionetics Oncology, Inc. focuses on the discovery and development of novel radiotherapeutics for the treatment of various oncology indications. Radionetics Oncology spun out of Crinetics Pharmaceuticals and is supported by Frazier Life Sciences, 5AM Ventures, DCVC Bio, Crinetics Pharmaceuticals, and GordonMD Investments. The company is advancing a pipeline of small molecule radioligands that target G-protein coupled receptors to treat a wide range of cancers, including adrenocortical carcinoma, breast cancer, and lung cancer. The company's platform technology uses nonpeptide, small molecule targeting to deliver therapeutic radioisotopes selectively to tumors expressing peptide receptors. The company's pipeline consists of multiple lead drug candidates, and they are conducting additional drug discovery efforts in collaboration with Crinetics Pharmaceuticals. The market for radiopharmaceuticals is expected to rise to $12.6 billion by 2027. The company was founded by Scott R. Struthers, and Paul A. Grayson has been the CEO since 2024. | Health Technology |
- Beurs
- Insiders
- Scott Struthers
- Ervaring